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Abstract
The sigma-2 receptor is expressed in higher density in proliferating (P) tumor cells versus quiescent (Q) tumor cells, thus
providing an attractive target for imaging the proliferative status (i.e., P:Q ratio) of solid tumors. Here we evaluate the utility
of the sigma-2 receptor ligand 2-(2-[18F]fluoroethoxy)-N-(4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl)-5-methyl-
benzamide, [18F]ISO-1, in two different rodent models of breast cancer. In the first study, small animal Positron Emission
Tomography (PET) imaging studies were conducted with [18F]ISO-1 and 18FDG in xenografts of mouse mammary tumor 66
and tracer uptake was correlated with the in vivo P:Q ratio determined by flow cytometric measures of BrdU-labeled tumor
cells. The second model utilized a chemically-induced (N-methyl-N-nitrosourea [MNU]) model of rat mammary carcinoma to
correlate measures of [18F]ISO-1 and FDG uptake with MR-based volumetric measures of tumor growth. In addition, [18F]ISO-
1 and FDG were used to assess the response of MNU-induced tumors to bexarotene and Vorozole therapy. In the mouse
mammary 66 tumors, a strong linear correlation was observed between the [18F]ISO-1 tumor: background ratio and the
proliferative status (P:Q ratio) of the tumor (R = 0.87). Similarly, measures of [18F]ISO-1 uptake in MNU-induced tumors
significantly correlated (R = 0.68, P,0.003) with changes in tumor volume between consecutive MR imaging sessions. Our
data suggest that PET studies of [18F]ISO-1 provide a measure of both the proliferative status and tumor growth rate, which
would be valuable in designing an appropriate treatment strategy.
Citation: Shoghi KI, Xu J, Su Y, He J, Rowland D, et al. (2013) Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1. PLoS
ONE 8(9): e74188. doi:10.1371/journal.pone.0074188
Editor: Zhaozhong Han, Vanderbilt University, United States of America
Received April 20, 2013; Accepted July 29, 2013; Published September 20, 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Funding provided by NIH/NCI contract N01-CN-43308, Siteman Cancer Center support grant P30CA091842, NIH grant CA102869 (www.nih.gov). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Drs. Robert Mach and Zhude Tu have a patent relating to the compound used in this work. The patent title is ‘‘Radiolabelled benzamide
analogues, their synthesis and use in diagnostic imaging’’ (patent # US 7,659,400 B2) awarded February 9, 2010. Isotrace Technologies, LLC, St. Charles, Missouri,
has a licensing agreement with Washington University School of Medicine for the commercialization of 18F-labeled sigma-2 receptor radiotracers developed in
the laboratory of Dr. R.H. Mach. Dr. Mach and Dr. Tu have no financial interests in Isotrace Technologies, nor are they paid consultants for the company. The
patent does not alter the authors’ adherence to the PLOS ONE policies on sharing data and materials.
* E-mail: shoghik@wustl.edu
Introduction
In the clinical management of cancer, major research efforts are
devoted to the optimization of chemo- and radio-therapies. To
that end, Positron Emission Tomography (PET) is widely used in
diagnosis and detection of cancer as well as in characterizing
therapeutic efficacy. One of the most commonly used radiophar-
maceuticals in oncological imaging is 18F-labeled 2-fluoro-2-
deoxy-D-glucose (FDG). FDG is an analog of glucose with the
oxygen at the 29 position replaced by fluorine and is taken up in
tissue via the same transport mechanism as glucose. Subsequent to
phosphorylation by the enzyme hexokinase to yield FDG-6-
phosphate, it is trapped in tumors, thus providing a non-invasive
measure of glucose utilization. PET measures of glucose metab-
olism have been used in the diagnosis and staging of cancer, as well
as in assessing efficacy of therapeutic intervention [1,2]. However,
it has been well established that FDG measures of tumor
metabolism do not correlate with tumor cell proliferation [3].
To that end, radiolabeled nucleosides, including [18F]fluorine-
labeled thymidine ([18F]FLT) which measures the salvage pathway
of DNA synthesis, have been developed as PET radiotracers for
measuring tumor proliferation rate [4].
Much like FDG, [18F]FLT is trapped within the cell as the
corresponding [18F]FLT-6-phosphate. This is attributed to the
action of the enzyme thymidine kinase-1 (TK1) which phosphor-
ylates the 69-hydroxyl group of [18F]FLT. TK1 is catalytically
active only during the S phase; therefore, [18F]FLT uptake
provides a measure of the S-phase fraction of a tumor. PET is a
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pulse labeling technique; i.e., the radiotracer is administered
intravenously and the imaging study is conducted within a narrow
period of time (30–120 min post-injection). Because tumors exhibit
asynchronous growth and contain cells in every phase of the cell-
cycle, G1, S, G2 and M phases, a pulse label measurement of the
S-phase fraction of a tumor with [18F]FLT is expected to
underestimate the total number of proliferating cells. Furthermore,
most solid tumors contain a population of quiescent tumor cells
(i.e., G0 cells) which exit the cell cycle due to nutrient deprivation.
Taken together, solid tumors are intrinsically heterogeneous and
contain populations of tumor cells that are either proliferating (P)
or quiescent (Q). Since radiotherapy and most chemotherapeutic
agents target proliferating tumor cells more effectively than
quiescent cells, knowledge of the proliferative status (i.e., P:Q
ratio) of a tumor can be used to design appropriate radio- or
chemo- therapy treatment strategies [5]. For example, hyper-
fractionated radiation therapy or cell-cycle-specific therapeutic
agents can be used in tumors with a high proliferative status [6,7].
Conversely, in tumors with a low proliferative status, non-cell-
cycle-specific agents can be used [6]. Finally, the proliferative
status of a tumor can be used to identify patients who will benefit
from therapies targeting proteins expressed in cycling cells but
absent in quiescent tumor cells [8,9].
Historically, the proliferative status of a solid tumor has been
measured by counting the number of Ki-67 positive cells in a
biopsy specimen. Ki-67 is a nuclear protein which is expressed in
all phases of the cell cycle of proliferating tumor cells except in
quiescent tumor cells [10]. Therefore, a PET radiotracer which
could image Ki-67 would provide a method for measuring the
proliferative status of solid tumors. Unfortunately, there are
currently no small molecules that bind with high affinity to Ki-67
reported in the literature which could serve as lead compounds for
PET radiotracer development. Consequently, attempts to develop
a PET radiotracer for imaging the proliferative status of a tumor
have relied on the identification of other biomarkers which behave
in a manner analogous to Ki-67. One possible candidate protein is
the sigma-2 receptor which has been shown to be overexpressed in
a variety of tumors [11–13]. In previous studies using the mouse
mammary tumor 66 cell line, the density of sigma-2 receptors was
found to be 10-fold higher in proliferating 66 versus quiescent 66
cells in vitro [14]. This observation was later confirmed in solid
tumor xenografts [15], suggesting that in vivo measures of the
sigma-2 receptor status may reflect the proliferative status of a
solid tumor. To that end, both 11C- and 18F-radiolabeled sigma-2
receptor ligands have been developed [16,17] and validated in a
variety of tumor models [15,17,18]. More recently, we have
published the first-in-human study using [18F]ISO-1 and reported
significant correlation between image measures of [18F]ISO-1 and
Ki-67 as a marker for tumor proliferation [19].
In this work, the sigma-2 receptor ligand 2-(2-[18F]fluor-
oethoxy)-N-(4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)bu-
tyl)-5-methylbenzamide, [18F]ISO-1 [16], was used to assess two
clinically-relevant properties of breast tumors: a) measurement of
the proliferative status of the tumor; and, b) prediction of the
volumetric change associated with tumor growth. The goal of the
first study was to correlate measures of [18F]ISO-1 uptake with
measures of tumor proliferative status as determined by BrdU-
labeling and ex vivo flow cytometry analysis performed on mouse
66 tumors. The second study employed a chemically-induced (i.e.,
N-methyl-N-nitrosourea [MNU]) rat model of mammary carcino-
ma [20] to correlate [18F]ISO-1 uptake with measures of tumor
growth rate determined by MRI-derived measures of tumor
volume. MNU-induced tumors are hormonally responsive and
display many of the histopathological characteristics of human
breast cancer [21]. Unlike clonogenic cancer models, individual in
situ MNU-induced tumors have a highly variable growth rate [22].
Therefore, multi-modality imaging was performed using small
animal MR and PET to correlate FDG and [18F]ISO-1 image-
derived PET outcome measures as a means of predicting future
changes in tumor volume. The MNU-model of breast cancer has
also been employed in the development and preclinical evaluation
of a number of chemotherapeutics. Therefore, a final goal of this
study was to assess the ability of FDG and [18F]ISO-1 to monitor
the response to chemotherapy. The therapeutic agents that were
evaluated in this work were bexarotene, which belongs to a class of
chemical compounds targeting the retinoid 6 receptors (RXR),
and Vorozole, a competitive inhibitor of the aromatase enzyme.
Materials and Methods
All animal studies were approved by an independent Washing-
ton University Animal Study Committee (Protocols #20090004,
20100107).
Synthesis of Radiolabeled Ligands
The tritiated sigma-2 receptor ligand [3H]RHM-1 was synthe-
sized by American Radiolabeled Chemicals, Inc. (St. Louis, MO)
Figure 1. Validation of in-vivo measures of tumor proliferation
using mammary 66 tumors. (A) Sum microPET images of sigma-2
ligand [18F]ISO-1 (top panel) and [18F]FDG (bottom panel) in 66
mammary tumors with varying P:Q ratios. Correlation between [18F]ISO-
1, [18F]FDG PET measures and P:Q ratio. Radiotracer tracer uptake tumor
to background ratio was plotted against the P:Q ratio and linear
regression analysis were performed. (B) [18F]ISO-1 tumor to background
ratio linearly correlates with P:Q ratio with a correlation coefficient
R = 0.92 and steep slope of 0.47; (C) [18F]FDG tumor to background ratio
slightly correlates with P:Q ratio, R = 0.37, with a slope of 0.16.
doi:10.1371/journal.pone.0074188.g001
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via O-alkylation of the corresponding phenol precursor [17];
chemical purity was greater than 99% and the specific activity of
the radiolabeled ligand was 80 Ci/mmol. FDG is routinely
synthesized at the Washington University Cyclotron facility. The
synthesis of [18F]ISO-1 has been described previously [15,17,18].
Validation of In-Vivo Measures of Tumor Proliferation
using Mammary 66 Tumors
Cell culture and implantation of 66 mammary
tumors. The mouse mammary 66 cells were cultured as
previously described [15]. Approximately 1.56106 cells/100 mL
were injected subcutaneously in the axillary regions of adult (20–
25 g) female nude mice to produce the bilateral tumors. Two to
three weeks after implantation, the P-cells in each tumor were
identified by labeling them with BrdU (Calbiochem-Novabiochem
Corp., La Jolla, CA, USA). Mice were injected with 100 mg/kg of
BrdU intraperitoneally (i.p.) every 8 h over a 48-h period (i.e. for
at least 2 cell cycle times). At the time of labeling, the tumors
ranged in size from 0.2 g to 1.0 g.
Imaging protocol and analysis. Prior to imaging mice were
anesthetized with 2% 2.5% isoflurane by inhalation via an
induction chamber. Anesthesia was maintained throughout the
imaging session by delivering 1%–1.5% isoflurane via a custom-
designed nose cone on a custom designed mice holder. The
mammary 66 tumor-bearing mice were secured side-by side and
placed inside the field of view (FOV) of the small animal imaging
PET scanner. After a transmission scan was performed, a 10-
minute static acquisition study was obtained approximately sixty
(60) minutes following injection of [18F]ISO-1 or [18F]FDG
(,200 mCi). Images were reconstructed using Filtered Back
Projection (FBP). Regions of interest (ROI) were manually drawn
on the tumors and appropriate reference regions delineated with
the software Acquisition Sinogram Image PROcessing using IDL’s
Virtual MachineTM (ASIPro VMTM) to obtain the radioactivity
uptake (nCi/mL) in each tumor and the surrounding background
tissue. Tumor to background radioactivity uptake ratios are
further compared with P:Q ratios described in the next sections.
BrdU labeling and flow cytometry analysis of the P:Q
ratio. Animals were euthanized and tumors were excised,
Figure 2. Characterization of the pharmacokinetics of [18F]ISO-1 and in-vitro determination of Sigma-2 Receptor Density. (A) A 2-
hour sum image depicting two MNU-induced tumors and the submandibular (S/M). The liver is evident in the coronal slices. (B) Time activity curves
of the two tumors, muscle, and the left-ventricular blood pool. Inset figure depicts kinetics at initial 5 min. (C) Representative saturation binding
experiments which show the total bound, non-specific bound and specific bound. (D) Representative Scatchard plots which were used to determine
Kd, Bmax and nH values.
doi:10.1371/journal.pone.0074188.g002
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minced and dissociated with an enzyme cocktail consisting of
0.04% collagenase, 0.04% pronase (,2500 PUK/100 mL) and
0.05% DNAase I in Waymouth’s medium without serum. After
incubating for 30–45 min at 37uC with continuous stirring, the
material was filtered through an 80-mesh screen. The filtrate was
centrifuged at 2256G at 4uC for 5 minutes, and the pellet
resuspended in Waymouth’s medium with 10% serum (to halt the
enzyme action) and held on ice while an aliquot was counted.
Single cell suspensions were then centrifuged again, resuspended
in phosphate-buffered saline (PBS) and fixed in 70% ethanol to
obtain a final concentration of 1–26107 cells/mL.
For the flow cytometry analysis, 1.56106 cells were first
incubated for 20 min at 37uC with 0.2 mg/mL of pepsin in 2 N
HCl–PBS, washed twice in PBS containing 0.5% fetal bovine
serum (FBS), and then incubated for 45 min with a mouse anti-
BrdU antibody conjugated to fluorescein isothiocyanate (Boehrin-
ger Mannheim, Indianapolis, IN, USA). The cells were then
washed in 1 mL of PBS containing 0.5% FBS and 0.5% Tween-
20, incubated for 30 min in RNAase (1 mg/mL) and stained with
propidium iodide (10 mg/mL). All flow cytometry was performed
using a Fluorescence-Activated Cell Sorting (FACS) instrument
(BD Biosciences, San Jose, CA, USA) equipped with an air-cooled
argon laser using an excitation wavelength of 488 nm. The gating
parameters in each experiment were set to insure that less than 2%
of the unlabeled cells had a fluorescence signal equivalent to that
of the weakest BrdU labeled cells in the tumor. Proliferative (P) to
quiescent (Q) cells ratio, P:Q ratio, is defined by BrdU labeled
positive cell fraction divided by negative cell fraction.
Correlation between [18F]ISO-1, FDG PET measures and
P:Q ratio. PET outcome measures were compared with the
Figure 3. MR Tumor volume measured at baseline and at 2-week intervals. (A) MR-derived tumor volume (B) Percent change in tumor
volume between consecutive imaging sessions for a select group of tumors. In analyzing the data, we exploited on the lack of consistency in tumor
increase and correlated changes in tumor volume to baseline measures of normalized [18F]ISO-1 uptake with the underlying notion that change in
tumor volume is predicated on the proliferative status of the tumor. (C) Representative time course imaging of MNU-induced tumors at baseline, 2
weeks, 4 weeks, 6 weeks, and 8 weeks with MRI, FDG and [18F]ISO-1. Note: time-course images are on differing color scale for each time point.
doi:10.1371/journal.pone.0074188.g003
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tumor proliferative status, BrdU labeled P:Q ratio. Radiotracer
tracer uptake in the whole tumor to the surrounding background
tissue ratio was plotted against the P:Q ratio and regression
analysis were performed using KaleidaGraph (Synergy Software,
Reading, PA, USA).
MNU-Induced Mammary Carcinoma Tumor Proliferation
and Response to Therapy
Animal study design. At 50–60 days of age, female Sprague-
Dawley rats were injected i.v. with 50 mg/kg MNU. Rats were
selected for the study when at least one palpable tumor was
apparent. The study employed 30 untreated MNU rats, 6 MNU
rats treated with bexarotene, and 6 MNU rats treated with
Vorozole. Bexarotene (220 mg/kg in the diet) and Vorozole
(1.25 mg/kg body weight by gavage) were provided for 8-weeks
following a baseline imaging session. Following the 8th week
imaging session, treatment was removed and rats were fed AIN-76
diet. Untreated rats were fed AIN-76 diet throughout the time
course of the study. Each rat was imaged with FDG over a 10-
week period at 2-week intervals to assess the metabolic state of
tumors, MRI to monitor tumor volume, and [18F]ISO-1 to assess
sigma-2 receptor status. A subset of untreated rats was used in
determination of sigma-2 receptor density described below. Due to
logistical constraints, MRI and PET images were typically
acquired within 61 day.
In-vitro determination of sigma-2 receptor
density. Sigma-2 receptor binding studies using tumor homog-
enate were conducted as previously described in other tissues [23].
Tumor membrane homogenate was diluted with 50 mM Tris-HCl
buffer, pH 8.0 and incubated for 60 min with [3H]RHM-1 in a
total volume of 150 mL at 25uC in 96 well polypropylene plates.
The concentrations of the radioligand ranged from 0.1–18 nM.
After incubation the reactions were terminated by the addition of
150 mL cold wash buffer, and the samples harvested and filtered
rapidly to a 96 well fiber glass filter plate. Each filter was washed
for a total of three washes. A liquid scintillation counter was used
to quantitate the bound radioactivity. Nonspecific binding was
determined from samples which contained 10 mM haloperidol.
The equilibrium dissociation constant (Kd) and maximum number
of binding sites (Bmax) were determined by a linear regression
analysis of the transformed data using the method of Scatchard
[24]. Data from saturation radioligand binding studies was
transformed to determine the Hill coefficient, nH, defined as
Figure 4. Correlation of PET measures of tumor proliferation to subsequent changes in tumor volume. (A) Correlation between
normalized FDG total uptake and percent change in volume between consecutive imaging sessions in untreated MNU rats. (B) Correlation between
normalized [18F]ISO-1 total uptake and percent change in volume between consecutive imaging sessions in untreated MNU rats. The correlation
coefficient is denoted by R= 0.68 significant at P,0.003. MRI and PET images were typically acquired within a 61 day, which could explain some of
the variability along the fitted line in Figure 7B.
doi:10.1371/journal.pone.0074188.g004
Figure 5. Normalized tumor volume in bexarotene- treated
MNU rats (A) and Vorozole (B). The legend in each plot denotes
tumor ID which matches tumor IDs of Figure 6, where applicable.
Treatment was provided as described in the methods section for 8
weeks. Following the imaging session at week 8, treatment was
withdrawn. (C) Time course of treatment is segmented into the short
term efficacy (week 0–2) and tumor response to treatment withdrawal
(weeks 8–10).
doi:10.1371/journal.pone.0074188.g005
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Figure 6. Time-course of FDG and [18F]ISO-1 mean SUV normalized to baseline for bexarotene- and Vorozile-treated MNU rats. Top
row: (A) FDG mean SUV and (B) [18F]ISO-1 mean SUV for bexarotene-treated rats. Bottom row: (C) FDG mean SUV and (D) [18F]ISO-1 mean SUV for
Vorozole-treated rats. Treatment was provided for 8 weeks. Following the imaging session at week 8, treatment was withdrawn. (E) Time course of
treatment is segmented into the short term efficacy (week 0–2) and tumor response to treatment withdrawal (weeks 8–10).
doi:10.1371/journal.pone.0074188.g006
Figure 7. SUV 10-minute sum images at 60-minute post-injection of FDG (top row) and [18F]ISO-1 (middle row). Bottom row depicts
the corresponding MR image at each time point (week 8 image is missing). Panel depicts treatment of tumor C1-1_L3 with bexarotene. Note that
following the imaging session at week 8, treatment was withdrawn.
doi:10.1371/journal.pone.0074188.g007
Receptor-Based Imaging of Tumor Proliferation





Bs is the amount of the radioligand bound specifically; L is the
concentration of radioligand. nH, Hill slope, was determined from
Hill plot of
log Bs= Bmax{Bsð Þ½  versus logL:
Pre-clinical MR imaging protocol. High-resolution MRI
was used to monitor tumor volume and morphology in all rats with
mammary tumors. MR images were collected in an Oxford
Instruments (Oxford, UK) 4.7 Tesla magnet (33 cm, clear bore)
equipped with 16-cm, inner-diameter, actively shielded Oxford
gradient coils (maximum gradient 18 G/cm, 200 msec rise time)
and high-power IEC gradient amplifiers (International Electric
Co, Helsinki, Finland). The magnet/gradients are interfaced with
a Varian (Palo Alto, CA) INOVA console and data were collected
using a Stark Contrast (Erlanger, Germany) 5-cm birdcage rf coil.
Prior to the imaging experiments, rats were anesthetized with
isoflurane and were maintained on isoflurane/O2 (1–1.5% v/v)
throughout the experiments. Multi-slice (20–25 slices), T2-weight-
ed, transaxial spin-echo images (Tr = 1.0–1.7 s; Te = 40 ms,
FOV=5 cm65 cm; slice thickness = 1 mm) were collected for
each rat. Tumor MR images appeared as distinct, hyperintense
regions, whose borders with normal tissue was easily and
unambiguously delineated. Tumor growth was measured by
manually segmenting individual tumors in each image and
calculating volumes using either Varian’s Image Browser software
or the public domain program ImageJ (http://rsb.info.nih.gov/ij).
Pre-clinical PET imaging protocol. Small-animal PET was
performed on either the microPETH Focus-120 [25] or Focus-220
[26] (Siemens Inc., Knoxville, TN). Both scanners were cross-
calibrated to a common source.
Dynamic PET Imaging with [18F]ISO-1. Dynamic imaging studies
were performed to characterize the pharmacokinetics of [18F]ISO-
1. Prior to imaging rats were anesthetized with 2% 2.5% isoflurane
by inhalation via an induction chamber. Anesthesia was main-
tained throughout the imaging session by delivering 1%–1.5%
isoflurane via a custom-designed nose cone and rat holder. MNU-
treated rats were secured and were placed inside the field of view
(FOV) of the small-animal imaging PET scanner. A bolus injection
of [18F]ISO-1 was administered via the tail vein approximately 5
seconds after the start of the PET scan and a dynamic acquisition
study was conducted for 120 min. Images were reconstructed
using Filtered Back Projection (FBP). ROIs were drawn on PET
images to characterize the kinetic time-course of [18F]ISO-1 in
tumor, muscle, and the left-ventricle (LV) to characterize its time-
course in blood. Muscle ROIs were drawn by placing a similar
ROI as the tumor ROI on the contralateral side of the animal.
Tumor-to-blood and tumor-to-muscle ratios were at steady state at
60 min suggesting that static imaging 60 min post-injection of
[18F]ISO-1 would capture tumor uptake of the ligand.
Static PET Imaging with FDG and [18F]ISO-1. Sixty (60) minutes
following injection of FDG (0.6–0.8 mCi) or [18F]ISO-1 (0.6–
0.8 mCi), rats were secured in a custom-designed acrylic
restraining device and placed inside the field of view (FOV) of
the small animal imaging PET scanner, as described above. A 10-
minute static acquisition ensued. Images were reconstructed using
Filtered Back Projection (FBP).
Multi-modality image analysis and
processing. Individual tumors in MRI and PET images were
carefully matched by an experienced technician to localize tumors.
The same technician processed all images to minimize inter-
operator variability. MRI images were used as landmarks to
identify tumors on PET images. Tumor FISO and FDG uptake
were consistently higher than surrounding tissue; hence, easily
distinguishable. Care was taken to draw ROIs on the entire tumor
boundary as visualized by a experienced technician. Volumes of
interest (VOIs) masks were drawn on PET images using the
program Analyze (Biomedical Imaging Resource, Mayo Clinic).
Masked images were subsequently imported into Matlab (Math-
works, Inc.) where the activity concentration in each voxel was
standardized by the activity injected and the animal weight
(SUV= (activity concentration in voxel)*(animal weight)/(activity
injected)). To facilitate data mining, a database was constructed for
each tumor that included the PET image mask, MRI-derived
volume, PET-derived volume, activity injected, animal weight,
and PET signal distribution within the tumor for each radiophar-
maceutical as a function of time. The dataset was used to tabulate
PET and MRI outcome measures, which were used to assess the
predictive capacity of FDG and [18F]ISO-1.
Correlation between FDG and [18F]ISO-1 PET outcome
measures and tumor growth pattern. PET outcome mea-
sures were compared with changes in MRI-derived volume
outcome measures. Specifically, all but PET volume outcome
measures were correlated against absolute and relative percent
change in consecutive volume measurements (i.e., consecutive
pairs: 0–2 weeks, 2–4 weeks, 4–6 weeks, 6–8 weeks, and 8–10
weeks). Let j denote the imaging session at week j (j=0, 2, 4, 6, 8,
10), PET outcome measures at week j were correlated to absolute
or percent change in volume measure between week (j+2) and j.
Absolute change in tumor volume is defined as the difference in
MRI-derived volume between week (j+2) and j, i.e., [V(j+2)-V(j)]
where V denotes volume. Relative percent change in volume is
defined as absolute change in volume relative to week j, i.e.,100*
[V(j+2)-V(j)]/V(j). In this data mining approach, the effects of
necrosis was accounted for by taking into account the distribution
of tracer uptake in the whole tumor. The strength of the
correlation between measures was determined by regression
analysis performed using the statistical package SPSS.
Assessing efficacy of therapy. Tumor response to bexar-
otene and Vorozole was characterized in terms of MR-derived
tumor load, metabolic state (FDG), and sigma-2 receptor status
([18F]ISO-1). Both MR- and PET-derived measures were
normalized to baseline for ease of analysis. Aside from tumor’s
response to therapy, we also considered the short-term efficacy 2-
weeks following treatment and effects of withdrawing treatment,
both characterized by tumor volume and changes in PET
outcomes measures relative to baseline. In reporting PET
measurements, treated tumors were classified by the nature of
their response to therapy: tumors that exhibited reduced volume
by the end of the study (or last time-point) are denoted by a solid
line; otherwise, tumors which did not respond to therapy were
denoted by a dashed line.
Statistical Analysis
Correlation analyses were performed using either Kaleida-
Graph (Synergy Software, Reading, PA, USA) or SPSS (IBM). In
assessing significance of correlation a P-value P,0.05 was
considered significant.
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Results
The goal of the current study was to assess the capacity of FDG
and the sigma-2 receptor ligand, [18F]ISO-1, to measure two
different clinically-relevant properties of solid tumors, proliferative
status (P:Q ratio) and tumor growth rate. FDG was chosen as the
reference ligand for comparison with [18F]ISO-1 since it is
currently the ‘‘gold standard’’ for PET oncological imaging
studies. Mouse mammary 66 tumors were used to correlate in-
vivo measures of radiotracer uptake to ex vivo measures of the P:Q
ratio since this cell line has been shown to produce solid tumors
having a highly variable P:Q ratio [15,27,28]. MNU-induced
tumors were also used as a more clinically relevant model of
mammary carcinoma, both in terms of etiology and progression.
MNU tumors were imaged for 10 weeks at 2-week intervals with
MRI to characterize tumor volume, FDG to measure tumor’s
metabolic state, and [18F]ISO-1 as a potential predictive imaging
marker for tumor proliferation. PET-derived outcome measures
were subsequently correlated to changes in tumor volume. Finally,
the response of MNU-induced tumors to two different chemo-
therapies used to treat breast cancer was assessed with both FDG
and [18F]ISO-1.
Correlation of FDG and [18F]ISO-1 Uptake with P:Q ratio
Tumors from the 66 cell line having a wide range of P:Q ratios
were imaged with either [18F]ISO-1 or FDG. As shown in
Figure 1A, [18F]ISO-1 yielded good contrast, with the tumor to
background ratio comparable to the metabolic radiotracer FDG.
A strong linear correlation of R= 0.87 was observed between the
tumor: background ratio and P:Q ratio for [18F]ISO-1 (Figure 1B),
whereas the correlation of FDG was poor, R= 0.37 (Figure 1C).
This study indicates that PET imaging targeting sigma-2 receptor
can potentially predict the proliferative status of a solid tumor
in vivo.
[18F]ISO-1 Kinetics and Sigma-2 Receptor Density in
MNU-induced Tumor
Representative images of [18F]ISO-1 in MNU-induced tumors
are depicted in Figure 2A. MNU-induced tumors exhibit
significant uptake of [18F]ISO-1 with minimal background uptake.
Additionally, there is high uptake of [18F]ISO-1 in the subman-
dibular (S/M) gland, a region known to exhibit high proliferative
activity [29] and demonstrated blocking of non-selective sigma 1/2
PET ligands [30]. The kinetics of [18F]ISO-1 in MNU-induced
tumors is depicted in Figure 2B. Tumor:blood and tumor:muscle
ratios achieved steady state after 60 min suggesting that static
imaging 60 min post-injection of [18F]ISO-1 would measure
tumor uptake. To characterize the receptor density (Bmax) of
[18F]ISO-1, direct saturation binding studies were carried out
using [3H]RHM-1 with membrane homogenate from a MNU-
induced rat mammary tumor. The saturation curve and Scatchard
plots are shown in Figure 2C and Figure 2D, respectively. The Kd
and Bmax values of the receptor-radioligand binding of [
3H]RHM-
1 were 4.66 nM and 2410 fmol/mg protein, respectively. The
mean of the Hill coefficient (nH values) was found to be near unity,
which is consistent with one-site fit. The high sigma-2 receptor
density and low non-specific binding further supports the use of
the MNU-induced mammary tumor model for the in vivo
evaluation of [18F]ISO-1.
Time Course of MNU-Induced Tumor Growth
Figure 3 displays the time-course of MNU-induced tumor
progression, both in terms of tumor growth (Figure 3A) and
percent change in tumor volume between consecutive imaging
sessions for select tumors (Figure 3B). There was a large variability
in tumor growth patterns (Figure 3B). In general, large tumors are
characterized by decreasing growth rate although the pattern is
not consistent. Moreover, Figure 3B suggests that the tumor’s
doubling time is not constant as it may be in fact be dictated by its
environment and other exogenous factors.
Representative time-course multi-modality imaging with MRI,
FDG, and [18F]ISO-1 is depicted in Figure 3C. Using the time-
course data, the tumor percent change in volume between
consecutive imaging sessions was determined. The normalized
FDG and [18F]ISO-1 SUV uptake at a given imaging time point
were subsequently correlated to the change in tumor volume by
the time of the next imaging session (2 weeks). While there was no
significant correlation between FDG SUV total uptake and
percent change in volume (Figure 4A), there is a significant
(P,0.003) correlation (R= 0.68) between [18F]ISO-1 total uptake
SUV and percent change in volume between consecutive imaging
session (Figure 4B).
Tumor Response to Treatment
Tumor load measurements. The therapeutic effects of
bexarotene and Vorozole on tumor load are depicted in Figure 5A
and Figure 5B, respectively. Bexarotene appeared to have the
stronger short-term efficacy at 2-weeks with a reduction in tumor
load, on average, by as much as 60% compared with Vorozole’s
20% reduction in tumor load. However, six weeks following the
initiation of treatment both agents induced strikingly reduced the
volume of most tumors. Removal of therapeutic agent from the
diet resulted in resurgence of tumors. We observed more rapid
tumor resurgence in rats treated with Vorozole compared with
bexarotene, suggesting a residual effect of bexarotene. In most
cases, MR imaging detected more tumors than PET owing to the
higher spatial resolution and larger field of view of the MR
scanner.
Bexarotene-treated rats. In bexarotene -treated rats (Figure
6AB), the short-term efficacy (initial 2-weeks) of both FDG and
[18F]ISO-1 were in agreement with increased tumor volume.
Tumor C1-3_R6 did not respond to therapy as characterized by
increased volume, FDG uptake, and enhanced ISO-1 signal in the
first 2-weeks. Interestingly, in tumor C1-1_L3 both FDG uptake
and ISO-1 signal increased between weeks 4–6 while tumor
volume remained negligible, as depicted in Figure 7. Removal of
bexarotene from the diet at 8 weeks resulted in rapid regrowth of
the tumor which was observed in the MRI and PET imaging
studies with both FDG and [18F]ISO-1.
Vorozole-treated rats. Short-term efficacy of Vorozole rats
was generally in agreement with changes in MR-derived volume
(Figure 6CD). Tumor C2-3_L3 was characterized by increased
volume between weeks 0–2 by as much 275% with a concomitant
increase in FDG uptake by approximately 140% but with a
reduced ISO-1 signal. By week 4, however, tumor volume was
80% of baseline (a reduction in volume by 295% from week 2).
Tumor C1-2_L3 exhibited a decrease in volume such that by week
8 the tumor was approximately 2% of the initial volume.
Following removal of Vorozole; however, tumor volume increased
to 46% from baseline.
Discussion
FDG PET is an invaluable tool for the clinical diagnosis,
staging, and monitoring the response to therapeutic interventions
in cancer patients [31–33]. In spite of this tremendous clinical
success, FDG has its limitations. One potential limitation of FDG
is in the imaging of cell proliferation; although tumor cells have a
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higher metabolic activity than surrounding normal tissue, the
uptake of FDG has shown inconsistent results with respect to the
correlation of tracer uptake and in vitro measures of cell
proliferation [3]. Therefore, there has been a concerted effort in
the field to develop alternative strategies for imaging cell
proliferation with PET. To date, efforts to image tumor
proliferation fall generally into two categories: 1) proliferation
rate via imaging the salvage pathway of DNA synthesis using
radiolabeled nucleosides which are substrates for TK-1 or TK-2,
an enzyme synthesized during the S-phase of the cell cycle in the
cytoplasm and mitochondria, respectively. Examples of this
approach include [18F]FLT [4] and [18F]FMAU [34]; and, 2)
proliferative status via targeting the sigma-2 receptor. The density
of sigma-2 receptors is 10-fold higher in proliferating 66 cells
versus quiescent 66 cells both in vitro and in vivo [15]. This inherent
property suggests that the sigma-2 receptor density may provide
an imaging biomarker for determining a tumor’s proliferative
status, and is likely to be useful in monitoring the antiproliferative
activity of potential therapeutic agents.
In order for a new PET radiotracer to be useful in oncological
imaging studies it must afford clinically-relevant information that
FDG cannot provide. In the first study, we performed breast
cancer imaging with PET to evaluate the ability of FDG and
[18F]ISO-1 to measure the proliferative status, which has been
operationally defined as the ratio of proliferating to quiescent
tumor cells (P:Q ratio). Previous studies have demonstrated that
the density of sigma-2 receptors in membrane homogenates
correlated with the P:Q ratio of mouse mammary 66 xenografts
[15]. In this work, we correlated the uptake of [18F]ISO-1 using
small animal PET imaging with flow cytometry measures of the
P:Q ratio in this mouse model of breast cancer. As indicated in
Figure 1, there was a high correlation between BrdU labeling-
derived measures of P:Q and in-vivo measures of [18F]ISO-1
uptake. In contrast, there was no correlation between FDG uptake
and tumor P:Q ratio. These results are consistent with the report
of Haberkorn and colleagues, who found no correlation between
FDG uptake and flow-cytometry measures of cell proliferation in a
rodent model of breast cancer [35]. Overall, our data indicate that
the sigma-2 receptor imaging strategy has a greater potential for
predicting the P:Q ratio of a solid tumor than FDG.
In a second study comparing these two radiotracers, the MNU-
induced rat mammary carcinoma model was used to evaluate the
predictive capacity of FDG and [18F]ISO-1 in characterizing
tumor growth rate as determined by MRI-derived changes in
tumor volume. MNU-induced tumors exhibited characteristic
wide range of tumor growth rates as evidenced by the normalized
tumor growth profile [22,36–38]. This variability in tumor volume
change in MNU-treated rats enabled us to correlate changes in
tumor volume with FDG and [18F]ISO-1 uptake; the relative
percent change in tumor volume between consecutive imaging
sessions was used as a measure of the tumors’ proliferation rate.
There was a significant correlation between [18F]ISO-1 uptake
and tumor growth rate as measured by MRI-derived changes in
tumor volume. In particular, [18F]ISO-1 uptake at a given
imaging week significantly correlated with relative change in
tumor volume between consecutive imaging sessions. Although
there are a number of factors which can influence tumor growth
rate, including cell cycle kinetics and birth-death equilibria of
tumor cells, the high correlation between [18F]ISO-1 uptake and
P:Q ratio described above suggests that the rapidly growing
MNU-induced tumors have a higher proliferative status than slow
growing MNU-induced tumors.
Several recent studies have reported the efficacy of bexarotene
and Vorozole on MNU-induced tumors. Of note, recent work by
Lubet et al. on the chemopreventive and therapeutic efficacy of
bexarotene [22] and Vorozole [38] provide some insight as to the
effect of the above mentioned agents. With regard to bexarotene,
Lubet and colleagues assessed the preventive effects of bexarotene
at 15, 92 and 272 ppm in diet which resulted in tumor preventive
effects of 40–100%. Furthermore, a high therapeutic dose of
bexarotene 250 ppm caused tumor regression in virtually all
animals within 5 weeks. [22]. In the present study we utilized a
dose of 250 mg/kg for 8 weeks and observed tumor regression of
at least 80% by week 6. In an earlier work, Christov and
colleagues [37] examined the therapeutic efficacy of Vorozole and
showed that it was highly effective in this ER+ model. In addition
to their therapeutic efficiencies, both agents strikingly decreased
tumor cell proliferation as assessed by BrdU incorporation within
7 days. Interestingly, studies in a neoadjuvant setting clearly
demonstrated that the aromatase inhibitor arimidex, which like
vorozole is a high affinity competitive inhibitor, results in profound
decreases in Ki67 staining within 2 weeks of treatment in clinical
ER+ tumors [39].
The time-course of PET imaging following treatment can be
divided into three segments: short-term response to treatment
(weeks 0–2), response to withdrawing of treatment at week 8
(weeks 8–10), and the period between weeks 2–8. The first two
segments are considered as challenges or stimuli to the tumor. In
the first challenge (short-term response), the pattern of FDG
uptake and signal due to [18F]ISO-1 generally agree with the
pattern of tumor growth for both bexarotene and Vorozole.
Interestingly, in tumor C2-3_L3 of the Vorozole cohort, decrease
in FISO uptake preceded subsequent reduction in tumor volume
by 2 weeks, similar to our observations in the untreated group.
When looking at PET and MRI time-course patterns most of the
tumors treated with Vorozole or bexarotene showed striking
regression by MRI within 4 weeks. Interestingly, in humans
treated in a neoadjuvant setting, where roughly 50% will show a
strong clinical response, it normally requires 4–6 months to
observe tumor regression by imaging. In the MNU-induced
tumors, profound decreases in tumor cell proliferation were
observed within 2 weeks of treatment. In the second challenge
(post-withdrawal of therapy), increased uptake of [18F]ISO-1
between weeks 8–10 suggested a resurgence of proliferating cells,
which was in agreement with the increase in tumor volume. A
decrease in [18F]ISO-1 uptake may be attributed to either a down-
regulation of sigma-2 receptors and/or cell death following
treatment. Taken together, further studies are needed to optimize
the timing and use of FDG, [18F]ISO-1, and other imaging
markers following treatment.
In summary, we studied the utility of FDG and [18F]ISO-1 in
characterizing two different properties of tumors, proliferative
status and tumor growth rate. [18F]ISO-1 showed a strong
correlation between tumor proliferative status whereas no such
correlation was observed with FDG. While we did not observe a
correlation between FDG uptake and changes in tumor volume,
we did observe a significant correlation between [18F]ISO-1
uptake and rate of tumor growth rate as defined by changes in
tumor volume between consecutive MRI imaging sessions. These
data suggest that a given value of [18F]ISO-1 uptake provides a
predictive measure of an expected change in tumor volume (i.e.,
growth rate), which attests to the tumor’s aggressiveness. It is
expected that such a measure would provide means to optimize a
given therapy or combination of therapies based on the kinetic
parameters of an individual tumor, thus improving the overall
management of cancer.
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